Stanley Capital Partners promotes Rodolphe Louvet to Principal

8 January 2024, London - Stanley Capital Partners (“Stanley Capital” / “SCP”), the specialist Healthcare and Resource Efficiency private equity investor with a Digital-First approach is delighted to announce the promotion of Rodolphe Louvet to Principal.

Rodolphe previously held the role of Senior Associate within Stanley Capital’s Investment Team and has worked closely with portfolio company, LXO Group, in its buy-and-build strategy since joining. Most recently, Rodolphe played a significant role in the acquisition of the prescription drug Nimodipine (under the brand name Nimotop®) from Bayer.

Rodolphe has also been a key member of SCP’s investment team contributing to the overall M&A strategy. This announcement represents Rodolphe’s second successive promotion in just 2 years since he started as an Associate with Stanley Capital in 2022.

Rodolphe continues to demonstrate a strong commercial and analytical understanding of both existing portfolio and potential new investment opportunities. Stanley Capital place a strong onus on the development of talent and are very pleased to be able to promote from within as it seeks to support an exciting firm roadmap for 2024 and beyond.

About Stanley Capital Partners LLP

Stanley Capital Partners is a European mid-market private equity firm, using research and technology to identify opportunities in the growing sustainable investment sectors of Healthcare and Resource Efficiency.

Stanley Capital targets businesses with the potential of generating EBITDA of $25m to $150m. We partner with management teams, in majority and minority transactions, to transform and grow companies through technological change, operational change and market consolidation.

Stanley Capital was founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt and has a team of over 100 professionals working closely together with its Leader Network and investors, sector and technology partners.